Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-093907
Filing Date
2024-08-08
Accepted
2024-08-08 16:06:13
Documents
64
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ntla-20240630.htm   iXBRL 10-Q 2285737
2 EX-10.1 ntla-ex10_1.htm EX-10.1 46713
3 EX-10.4 ntla-ex10_4.htm EX-10.4 126787
4 EX-31.1 ntla-ex31_1.htm EX-31.1 13612
5 EX-31.2 ntla-ex31_2.htm EX-31.2 13632
6 EX-32.1 ntla-ex32_1.htm EX-32.1 8307
  Complete submission text file 0000950170-24-093907.txt   8527312

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ntla-20240630.xsd EX-101.SCH 1197636
67 EXTRACTED XBRL INSTANCE DOCUMENT ntla-20240630_htm.xml XML 1352795
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37766 | Film No.: 241188208
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)